中生联合(03332.HK)拟8月22日举行董事会会议批准中期业绩

Core Viewpoint - The company, China National Pharmaceutical Group Corporation (中生联合), has scheduled a board meeting on August 22, 2025, to review its mid-term performance for the six months ending June 30, 2025, and to consider the distribution of an interim dividend, among other matters [1] Group 1 - The board meeting is set for August 22, 2025 [1] - The meeting will focus on the mid-term results for the period ending June 30, 2025 [1] - The company will also discuss the potential distribution of an interim dividend [1]